MBD6 promoted a more open chromatin state and increased transcription in stem cells in malignancies with TET2 depletion, suggesting a potential therapeutic avenue for targeting TET2‐mutant hematological malignancies via the development of MBD6 inhibitors. The gene discussed is MBD6; the disease is hematologic disorder.